摘要
目的: 探讨促红细胞生成素(EPO)对晚期非小细胞肺癌(NSCLC)化疗所致贫血的疗效。方法:46例晚期NSCLC采用以顺铂为主联合化疗方案所致贫血患者分两组,EPO治疗组26例患者给予皮下注射EPO,剂量为150 ug/kg,3次/周,当血红蛋白(Hh)值>150g/L时,EPO剂量减半;对照组20例不给予EPO治疗,给予口服利血生20 mg/次,3次/d。结果:治疗后4周起EPO治疗组患者血红蛋白(Hb),红细胞压积(HCT)、红细胞总数(RBC)值均明显上升,与治疗前相比差异有显著性(P值<0.001),与对照组相比差异有显著性(P值<0.005)。EPO治疗组总有效率为92.3％,与对照组(66.7％)相比差异有显著性(P<0.05)。结论:EPO对晚期非小细胞肺癌采用以顺铂为主联合化疗方案所致贫血有肯定的疗效。
Purpose: To investigate the effect of erythropoietin (EPO) therapy for anemic patients with non-small cell lung cancer( NSCLC) on combination chemotherapy. Methods: 46 anemic patients with late NSCLC on combination chemotherapy of cisplatin-based were divideet into 2 groups: with or without EPO, The EPO treatment group was consisted of 26 patients, the EPO dose was 150 u,g/kg, 3 times per week, when Hb > 150 g/L, the dose of EPO was decreased by half. The control group consisted of 20 patients given Leucogenum, the dose was 20 mg every time, 3 times per day. Results: From the fourth week after therapy, the Hb, HCT, RBC of the EPO treatment group was significantly higher than prior to treatment( P < 0. 001), and also higher than that of the control( P < 0. 005) . The overall response rate of the EPO treatment group( 92. 3%) was significantly higher than that of the control (66. 7%) ( P < 0. 05). Conclusions: The effect of anemic patients with late NSCLC on cisplatin-based combination chemotheraphy given EPO was definitely positive.
出处
《中国癌症杂志》
CAS
CSCD
2003年第4期356-358,共3页
China Oncology
